Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Richa Rai, PhD, Foramben Patel, MS, Stella Melana, PhD, Jonathan Feld, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142908

Published: 2020

Journal Articles

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Jonathan Feld, MD, Erin P. Demakos, RN, Rosalie Odchimar-Reissig, RN, Douglas Tremblay, MD, Saudia Alli, NP, Darshanie Sewah, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138969

Published: 2020

Journal Articles

T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG

Jonathan Feld, MD, Jane Houldsworth, PhD, Asha Reddy, MS, Zinnia Mai, BS, Shafinaz Hussein, MD, Shyamala C. Navada, MD, Lewis R. Silverman, MD, Meenakshi Mehrotra, PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-143083

Published: 2020

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Camille Bigenwald, MD, Amir Horowitz, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Richa Rai, PhD, Stella Melana, PhD, Erin P. Demakos, RN, Miriam Merad, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 2986.

https://doi.org/10.1182/blood-2019-124887

Published: 2019

Journal Articles

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Jonathan Feld, MD, Francesca Schieppati, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4260.

https://doi.org/10.1182/blood-2019-128656

Published: 2019

Journal Articles

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Guillermo Garcia-Manero, MD, Shyamala C. Navada, MD, Pierre Fenaux, MD PhD, Patrick S. Zbyszewski, MBA, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4268.

https://doi.org/10.1182/blood-2019-132149

Published: 2019

Journal Articles

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4231.

https://doi.org/10.1182/blood-2019-130747

Published: 2019

Journal Articles

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2018-99-119266

Published: 2018

Journal Articles

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

John Roboz, Shyamala C. Navada, MD, Sool Yeon Cho, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2018-99-115169

Published: 2018

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Lewis R Silverman, MD, Pratima Chaurasia, PhD, Stella Melana, PhD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, BA, BSN, MSN, RN, Shyamala C. Navada, MD, E. Premkumar Reddy, PhD BSc, MSc

Blood (2017) 130 (Supplement 1): 4235.

https://doi.org/10.1182/blood.V130.Suppl_1.4235.4235

Published: 2017

Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 3167.

https://doi.org/10.1182/blood.V128.22.3167.3167

Published: 2016

Journal Articles

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Guillermo Garcia-Manero, MD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Bernard Brownstein, MD, Hannes Loferer, PhD, Nozar Azarnia, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Lewis R. Silverman, MD

Blood (2016) 128 (22): 4324.

https://doi.org/10.1182/blood.V128.22.4324.4324

Published: 2016

Journal Articles

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Pierre Fenaux, MD PhD, Aref Al-Kali, MD, Shyamala C. Navada, MD, Maria R. Baer, MD, Azra Raza, MD, Peter Greenberg, MD, Karl-Anton Kreuzer, MD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Gail J. Roboz, Valeria Santini, MD, Uwe Platzbecker, MD, Michael E. Petrone, MD MPH, Bernard Brownstein, MD, Patrick Simon Zbyszewski, MBA, Manoj Maniar, PhD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 2011.

https://doi.org/10.1182/blood.V128.22.2011.2011

Published: 2016

Journal Articles

Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Ghulam J Mufti, FRCP, FRCPath, MD, Lewis R. Silverman, MD, Steven Best, PhD, Steve Fructman, MD, Nozar Azarnia, PhD, Michael E. Petrone, MD MPH, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 5257.

https://doi.org/10.1182/blood.V126.23.5257.5257

Published: 2015

Journal Articles

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

John F. Seymour, MBBS, PhD, Lewis R. Silverman, MD, Hartmut Döhner, Prof. MD, Pierre Fenaux, MD PhD, Ghulam J. Mufti, MD PhD, Valeria Santini, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, Lela M. Lucy, PhD, Stephen Songer, PharmD, Donna Dougherty, BSN, Randy Hinkle, RPh, MBA, Dominique Gambini, MD, C.L. Beach, PharmD, Hervé Dombret

Blood (2015) 126 (23): 3754.

https://doi.org/10.1182/blood.V126.23.3754.3754

Published: 2015

Journal Articles

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Shyamala C. Navada, MD, Lewis R. Silverman, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Pierre Fenaux, MD PhD, Steve Fruchtman, MD, Nozar Azarnia, PhD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 910.

https://doi.org/10.1182/blood.V126.23.910.910

Published: 2015

Journal Articles

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

Francesca Schieppati, Erin P. Demakos, RN, CCRN, Odchimar Rosalie-Reissig, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2015) 126 (23): 1704.

https://doi.org/10.1182/blood.V126.23.1704.1704

Published: 2015

Journal Articles

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Francois Wilhelm, MD PhD, Katherine Hearn, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Nozar Azarnia, PhD, Lewis R. Silverman, MD

Blood (2014) 124 (21): 3252.

https://doi.org/10.1182/blood.V124.21.3252.3252

Published: 2014

NARROW

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only